Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
140 participants
INTERVENTIONAL
2018-06-16
2019-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
NCT02225184
SMART Trial: Community Stigma Reduction
NCT05075330
SMART Trial: Intrapersonal and Interpersonal Stigma Reduction
NCT04693416
Safety and Health Intervention Project
NCT02152397
SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence
NCT04080180
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nutraceutical, KB220Z
A nutraceutical pill containing pro-dopamine precursors
KB220Z
Acts to enhance dopamine
Placebo
A placebo that looks the same and is in a similar bottle
Placebo
A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KB220Z
Acts to enhance dopamine
Placebo
A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be willing to undergo pharmacogenetic testing
* Must be able to swallow tablets
Exclusion Criteria
* Clinical Diagnosis of Schizophrenia
* Clinical Diagnosis of a terminal disorder
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Home Development Group
UNKNOWN
Geneus Health
UNKNOWN
Howard University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marjorie Gondre-Lewis
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Howard University
Washington D.C., District of Columbia, United States
Medical Home Development Group
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.